Therapeutic Area: AAT Deficiency
The InnovAATe Study is a Prospective Phase III Multi-center, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” in Adult Patients with Alpha-1 Antitrypsin Deficiency, followed by an Open-Label Extension.
Visit innovaate-study.com to learn more about the study.
Therapeutic Area: CMV Disease
CYTOGAM is the only plasma-derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause of organ rejection post-transplant.
Therapeutic Area: Ocular Diseases
Human plasma-based eye drops for potential treatment of several ocular conditions.